Table 3

Relative changes in plasma parameters upon insulin-stimulation during the hyperinsulinemic-euglycemic clamp

Diabetic patients (n = 11)

Controls (n = 10)

Before treatment

After treatment

Albumin (%)

-3.4 ± 0.9^#

-3.1 ± 1.1^#

-6.0 ± 0.8^#

Total cholesterol (%)

0.4 ± 0.8

-1.7 ± 1.4

0.4 ± 0.7

LDL cholesterol (%)

2.5 ± 2.1

-0.5 ± 1.3

2.3 ± 1.1

HDL cholesterol (%)

1.3 ± 2.7

0.8 ± 1.6

2.7 ± 1.3

Triglycerides (%)

-5.2 ± 6.4

-14.3 ± 5.5^a,c

-16.7 ± 4.5^a

FFA (%)

-58.9 ± 3.4^a,b

-65.0 ± 4.1^a,c

-80.1 ± 2.6^a

hsCRP (%)

-4.7 ± 2.7

-4.9 ± 2.4

5.5 ± 4.5

TNFα (%)

12.0 ± 6.6

-9.1 ± 7.9^c

12.1 ± 14.2

IL6 (%)

13.7 ± 6.7

16.4 ± 7.9

23.5 ± 9.0^a

MCP1 (%)

-9.1 ± 1.8^a

-3.7 ± 4.0

-11.1 ± 4.1^a

^# Plasma albumin changed (p < 0.05) during the clamp because of increase in blood volume due to fluid infusion. Therefore, all plasma parameters are corrected for changes in plasma albumin concentration and presented as mean ± SEM

^a Significant change (P < 0.05) in response to insulin

^b Significant difference between type 2 diabetic patients and BMI-matched controls in response to insulin

^c Significant change (P < 0.05) effect of rosiglitazone treatment on the response to insulin in type 2 diabetic patients

Bragt et al. BMC Endocrine Disorders 2009 9:8   doi:10.1186/1472-6823-9-8